Article Text

Download PDFPDF

2022-RA-1509-ESGO The MULTISENT study: Analysis of survival according to the volume of sentinel lymph node disease
  1. Silvia Cabrera1,
  2. Natalia R Gomez-Hidalgo1,
  3. Virginia Garcia-Pineda2,
  4. Vicente Bebia1,
  5. Pere Fuste3,
  6. Paula Alonso4,
  7. Francesc Fargas5,
  8. Sergi Fernández6,
  9. Pablo Padilla-Iserte7,
  10. Tomas Gómez-Rodríguez8,
  11. Reyes Oliver9,
  12. Enrique Chacón10,
  13. Alfonso Quesada11,
  14. Fernando Roldán-Rivas12,
  15. Anna Torrent13,
  16. Carlos Andrés López-de la Manzanara14,
  17. Octavio Arencibia15,
  18. Antonio Gil-Moreno1,
  19. on behalf of the MULTISENT STUDY GROUP
  1. 1Gynecologic Oncology, Hospital Universitari Vall d’Hebron, Barcelona, Spain
  2. 2Hospital Universitario La Paz, Madrid, Spain
  3. 3Hospital Clínic, Barcelona, Spain
  4. 4Hospital Universitario Gregorio Marañón, Madrid, Spain
  5. 5Hospital Universitario Dexeus, Barcelona, Spain
  6. 6Hospital Universitario de Bellvitge, Barcelona, Spain
  7. 7Hospital Universitario La Fe, Valencia, Spain
  8. 8Hospital Universitario Virgen de la Victoria, Málaga, Spain
  9. 9Hospital Universitario 12 de Octubre, Madrid, Spain
  10. 10Clínica Universitaria de Navarra, Pamplona, Spain
  11. 11Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain
  12. 12Hospital Clínico Universitario de Zaragoza, Zaragoza, Spain
  13. 13Hospital Universitari Son Espases, Palma de Mallorca, Spain
  14. 14Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
  15. 15Hospital Universitario Gran Canarias Doctor Negrín, Las Palmas de Gran Canaria, Spain


Introduction/Background The MULTISENT study is an initiative that aims to analyze the clinical application of sentinel lumph-node(SLN) technique in Spain. This abstract presents the second objective of the study, aiming to evaluate the rate of SLN metastases detected and the impact of the volume of the disease on the survival of the patients.

Methodology Multicenter retrospective study in which twenty-nine Spanish centers were enrolled. Patients operated between 2015–2021 with preoperative clinical stage I-II EC and undergoing SLN mapping as part of their surgical protocol were included. SLN mapping was performed with three different tracers(ICG, ICG + 99mTC and 99mTC alone or in combination with blue dyes) and different sites of injections were used(cervical, uterus and both). Pelvic lymphadenectomy was performed in 54% of the cohort and aortic lymphadenectomy in 26%, according to the preoperative risk of the patient and the institutional protocol. OSNA or ultra-staging protocols with immunohistochemistry were used to study SLN specimens.

Results 1182 eligible patients were analyzed. Median age was 62.7 y(55.9–70.5 y). Median number of resected SLNs was 2(range 1–3) per patient. Minimally-invasive surgeries were performed in 1127(95%) patients. 117 patients(9.9%) had positive SLNs, 68 patients(5.7%) with macrometastases and 49(4.2%) with low-volume disease(24 micrometastases and 25 isolated tumour cells, ITC). Patients with macrometastases had a significantly higher proportion of non-endometrioid histologies, grade 3, lymph-vascular invasion, and received more extensive surgery and adjuvant chemotherapy. False-negative rate(FNR) of the SLN technique in the cohort was 1.6%. With a median follow up of 1.8 y(0.9–3 y), patients with macrometastases in SLN showed a decreased overall survival(OS) and disease-free survival(DFS) when compared to patients with negative SLN, ITC or micrometastases (figure1).

Abstract 2022-RA-1509-ESGO Figure 1

Conclusion SLN is a feasible technique with high sensitivity and low false-negative rate. Patients with macrometastasis showed the worst results in terms of OS and DFS.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.